Login to Your Account



MS Pipeline Growing

Biogen Gains Rights To UCB's CDP323 In $200M Partnership

By Jennifer Boggs


Wednesday, October 4, 2006
Adding a fifth product to its portfolio of approved and investigational multiple sclerosis therapies, Biogen Idec Inc. agreed to collaborate on CDP323, an oral alpha-4 integrin inhibitor discovered by UCB. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription